<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Open Forum Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Open Forum Infect Dis</journal-id><journal-id journal-id-type="publisher-id">ofid</journal-id><journal-title-group><journal-title>Open Forum Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">2328-8957</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">5630830</article-id><article-id pub-id-type="doi">10.1093/ofid/ofx163.1077</article-id><article-id pub-id-type="publisher-id">ofx163.1077</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstracts</subject><subj-group subj-group-type="category-toc-heading"><subject>Poster Abstract</subject></subj-group></subj-group></article-categories><title-group><article-title>No Emergent Resistance in HIV-1 Infected Virologically-Suppressed Subjects Who Switched to R/F/TAF</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Porter</surname><given-names>Danielle</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Kulkarni</surname><given-names>Rima</given-names></name><degrees>BS</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Cao</surname><given-names>Huyen</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Sengupta</surname><given-names>Devi</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>White</surname><given-names>Kirsten</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib></contrib-group><aff id="AF0001">
<label>1</label>
<institution>Gilead Sciences</institution>, <addr-line>Foster City, California</addr-line></aff><author-notes><fn id="fn-0001"><p>
<bold>Session:</bold> 156. HIV: Antiretroviral Therapy</p><p>
<italic>Friday, October 6, 2017: 12:30 PM</italic>
</p></fn></author-notes><pub-date pub-type="collection"><season>Fall</season><year>2017</year></pub-date><pub-date pub-type="epub" iso-8601-date="2017-10-04"><day>04</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>04</day><month>10</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>4</volume><issue>Suppl 1</issue><issue-title>ID Week 2017 Abstracts</issue-title><fpage>S427</fpage><lpage>S427</lpage><permissions><copyright-statement>&#x000a9; The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</copyright-statement><copyright-year>2017</copyright-year><license license-type="cc-by-nc-nd" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p></license></permissions><self-uri xlink:href="ofx163.1077.pdf"/><abstract><title>Abstract</title><sec id="s1"><title>Background</title><p>GS-US-366-1216 and GS-US-366-1160 are randomized, double-blind, phase 3b studies evaluating the safety and efficacy of switching to rilpivirine/emtricitabine/tenofovir alafenamide (R/F/TAF) from R/F/tenofovir disoproxil fumarate (TDF) or efavirenz (EFV)/F/TDF, respectively, in HIV-1-infected virologically-suppressed subjects. At Week 48, switching to R/F/TAF was non-inferior to staying on R/F/TDF (94% vs. 94%, respectively) or EFV/F/TDF (90% vs. 92%) for HIV-1 RNA &#x0003c;50 c/mL (virologic success) by FDA snapshot analysis. Here, we present integrated resistance analyses of these two studies through Week 48.</p></sec><sec id="s2"><title>Methods</title><p>Historical genotypes were collected when available. Subjects in the resistance analysis population (subjects with HIV-1 RNA &#x02265;400 c/mL at virologic failure, discontinuation, or Week 48) had genotypic/phenotypic analyses at failure for protease and reverse transcriptase (RT; PhenoSense GT, Monogram). Subjects with post-baseline resistance mutations detected had their baseline proviral DNA analyzed retrospectively (GenoSure Archive, Monogram).</p></sec><sec id="s3"><title>Results</title><p>Of the 1504 randomized and treated subjects, resistance development was analyzed for 7 subjects (0.9%; 7/754) on R/F/TAF, 1 subject (0.3%; 1/313) on R/F/TDF, and 2 subjects (0.5%; 2/437) on EFV/F/TDF. No R/F/TAF (0%) or R/F/TDF (0%) subjects developed primary NNRTI or NRTI resistance mutations. One EFV/F/TDF subject (0.2%; 1/437) developed primary NNRTI and NRTI resistance mutations (NNRTI: Y188L; NRTI: M184V). Three subjects on R/F/TAF had virologic rebound with mutations also detected at baseline by proviral DNA analysis. Historical genotypes were available for 527 subjects; virologic success rates were high among subjects with pre-existing mutations (Table 1).</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Virologic success rates of subjects with mutations by historical genotype.</p></caption><table frame="box" rules="groups"><thead><tr><th align="left" rowspan="2" valign="bottom" colspan="1">RT mutation</th><th align="center" colspan="3" valign="bottom" rowspan="1">Subjects with success/subjects with mutation (%)</th></tr><tr><th align="left" valign="bottom" rowspan="1" colspan="1">R/F/TAF</th><th align="center" valign="bottom" rowspan="1" colspan="1">R/F/TDF</th><th align="center" valign="bottom" rowspan="1" colspan="1">EFV/F/TDF</th></tr></thead><tbody><tr><td align="left" valign="bottom" rowspan="1" colspan="1">K101E</td><td align="center" valign="bottom" rowspan="1" colspan="1">1/1 (100%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">0</td><td align="center" valign="bottom" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">K103N</td><td align="center" valign="bottom" rowspan="1" colspan="1">10/11<sup>a</sup> (91%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">6/7<sup>a</sup> (86%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">1/1 (100%)</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">E138A/K</td><td align="center" valign="bottom" rowspan="1" colspan="1">2/3<sup>a</sup> (67%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">2/2 (100%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">M184V</td><td align="center" valign="bottom" rowspan="1" colspan="1">1/2<sup>a</sup> (50%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">1/1 (100%)</td><td align="center" valign="bottom" rowspan="1" colspan="1">0</td></tr></tbody></table><table-wrap-foot><fn id="fn-0002"><p>
<sup>a</sup>1 subject discontinued prior to Week 48 with HIV-1 RNA &#x0003c;50 c/mL.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s6"><title>Conclusion</title><p>No emergent resistance to any of the components of R/F/TAF was detected through 48 weeks after switching. Virologic success rates were high among subjects with pre-existing mutations.</p></sec><sec id="s5"><title>Disclosures</title><p>
<bold>D. Porter</bold>, Gilead Sciences, Inc.: Employee and Shareholder, Salary; <bold>R. Kulkarni</bold>, Gilead Sciences, Inc.: Employee and Shareholder, Salary; <bold>H. Cao</bold>, Gilead Sciences, Inc.: Employee and Shareholder, Salary; <bold>D. Sengupta</bold>, Gilead Sciences Inc.: Employee and Shareholder, Salary; <bold>K. White</bold>, Gilead Sciences, Inc.: Employee and Shareholder, Salary</p></sec></abstract><counts><page-count count="1"/></counts></article-meta></front></article>